(Q43264239)

17 November 2017

Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study (English)

1 reference

17 November 2017

1 reference

1 reference

1 reference

5

Toshihiko Doi

1 reference

17 November 2017

12

Atsushi Ohtsu

1 reference

17 November 2017

1

Narikazu Boku

1 reference

17 November 2017

4

Kuniaki Shirao

1 reference

17 November 2017

Seiichiro Yamamoto

2

1 reference

17 November 2017

Haruhiko Fukuda

3

1 reference

17 November 2017

Akira Sawaki

6

1 reference

17 November 2017

Wasaburo Koizumi

7

1 reference

17 November 2017

Hiroshi Saito

8

1 reference

17 November 2017

Kensei Yamaguchi

9

1 reference

17 November 2017

Hiroya Takiuchi

10

1 reference

17 November 2017

Junichiro Nasu

11

1 reference

17 November 2017

Gastrointestinal Oncology Study Group of the Japan Clinical Oncology Group

13

1 reference

17 November 2017

7 October 2009

1 reference

Lancet Oncology Commission

17 November 2017

1 reference

17 November 2017

10

1 reference

17 November 2017

11

1 reference

17 November 2017

1063-1069

1 reference

Global cancer statistics, 2002

17 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Initial or delayed chemotherapy with best supportive care in advanced gastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970259-1

7 January 2021

10.1016/S1470-2045(09)70259-1

Identifiers

DOI

1 reference

17 November 2017

1 reference